Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) regularly issues detailed news releases about its work in recombinant spider silk and bioengineered fibers. The company describes itself as a world leader in spider silk technology and uses its news flow to report on production milestones, facility expansions, scientific progress, and commercial engagements.
News items often highlight advances in the company’s BAM-1 and BAM-1 Alpha hybrid silkworm lines, including selective breeding achievements that increase cocoon shell weight, throughput, and production efficiency. Kraig Biocraft Laboratories also reports on the launch and completion of spider silk production cycles, the deployment of BAM-1 Alpha as its primary production hybrid, and the integration of diapause egg management into its rearing operations.
Another recurring theme in KBLB news is the build-out of production infrastructure in Southeast Asia. Releases cover topics such as taking possession of additional silkworm rearing centers, relocating facilities to protected highlands, and maintaining multiple, parallel production sites to support scalability and resilience. The company also reports on securing usage rights to government-owned mulberry gardens and taking control of mulberry fields dedicated to its operations, emphasizing feedstock security and vertical coordination.
Investors and observers can also find updates on commercial and research developments, including pilot programs with a globally recognized performance sports apparel brand and announcements about scientific leadership and breakthroughs in advanced fibers and bioengineered materials. Together, these news items provide an ongoing view into Kraig Biocraft Laboratories’ efforts to expand spider silk production capacity, refine its technology, and pursue high-value applications in performance textiles, technical apparel, and other markets.
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has secured a business license to commence operations in Cambodia. This expansion is part of the company's 2025 strategy to scale up and diversify its spider silk production capabilities. The new Cambodian facility was chosen for its favorable climate and infrastructure to support the company's production scale-up initiatives.
COO Jon Rice emphasized that this license represents more than geographic expansion, highlighting Cambodia's strategic importance in their production diversification efforts. The company continues to invest in research and infrastructure to enhance its proprietary recombinant spider silk technologies, aiming to strengthen its production pipeline and establish a global presence for commercial biomaterials deployment.
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has announced the successful completion of its March/April spider silk production cycle and the commencement of its May production run. The company reports meeting internal performance benchmarks and production targets, demonstrating progress in its 2025 production scale-up plan.
The achievement builds upon operational and technical advancements from 2024, with production activities in both Vietnam and the U.S. showing consistent execution. This progress supports Kraig Labs' strategy to transition from pilot-scale to commercial-scale production of recombinant spider silk for multiple markets.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced significant progress in its recombinant spider silk production operations. The company is currently executing its largest-ever production batch, with the first half already completed and cocoons being prepared for silk reeling. The second half is expected to finish within 14 days.
The current production run represents a milestone as the first simultaneous batches of BAM-1 produced in their newest facilities. Initial results show promising performance of the BAM-1 hybrids and effectiveness of the expanded infrastructure. The company has also completed production of all BAM-1 hybrid eggs scheduled for release next month, ensuring consistent supply for upcoming production cycles.
According to CEO Kim Thompson, this successful execution of simultaneous production demonstrates their technology's scalability from batch processing to continuous flow manufacturing.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced the successful implementation of a next-generation molecular biology and gene-splicing platform. This advancement represents a significant upgrade in the company's genetic engineering capabilities for spider silk production.
The company has already validated the technology by creating a new transgenic silkworm, which is currently undergoing evaluation testing and commercial application assessment. Kraig Labs is experimenting with two such platforms and plans to adopt one for all ongoing and future commercial silkworm development programs.
This technological upgrade is expected to enable more precise, efficient, and versatile DNA manipulation, accelerating the R&D pipeline for advanced materials and enhancing material performance. The company is actively transitioning all silkworm biotechnology programs to these next-generation platforms to improve efficiency, consistency, and performance in spider silk production.
Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk-based super materials, has appointed Dr. Xiaoli Zhang as Director of Molecular Biology. Dr. Zhang, recognized for her groundbreaking work in spider silk and transgenic silkworms research, has already achieved significant breakthroughs in developing new spider silk-based fibers with enhanced capabilities.
The appointment strengthens the company's R&D capabilities as it accelerates the transition from laboratory development to large-scale commercialization of these revolutionary materials. Dr. Zhang's expertise in genetic engineering and bioengineering, backed by peer-reviewed publications, has been important in optimizing the company's genetic engineering of silkworms for spider silk production.
Kraig Biocraft Laboratories (OTCQB: KBLB) has secured four registered trademarks for its SpydaSilk® brand, marking a significant milestone in its commercialization strategy for recombinant spider silk technology. SpydaSilk®, a Singapore-based joint venture founded in 2021, serves as a direct-to-consumer marketing channel for the company's spider silk materials.
The company is pursuing a dual-track approach by developing SpydaSilk® as a standalone brand while seeking collaborations with industry leaders in luxury fashion and high-performance apparel. Kraig Labs' proprietary recombinant spider silk fibers combine strength, elasticity, and softness, targeting high-value applications.
With recent production expansion, the company focuses on optimizing spider silk output and finalizing product designs for commercialization, aiming to accelerate technology adoption and drive revenue growth through this blended strategy.
Kraig Biocraft Laboratories (OTCQB: KBLB) has achieved a groundbreaking scientific milestone by successfully engineering the largest known spider silk gene insert into silkworm, nearly doubling the previous record. This breakthrough, led by Research Manager Dr. Xiaoli Zhang, enables the creation of larger, more complex proteins with unique mechanical properties for incorporation into silk fibers.
The achievement represents a significant advancement in developing high-performance biomaterials with enhanced strength, flexibility, and performance potential. While focusing on this innovation, the company maintains its commitment to commercializing its current recombinant spider silk production strains for applications in performance textiles, defense, and industrial sectors.
The company emphasizes that the significance lies not in the size of the genetic insert but in the information it carries, potentially unlocking new possibilities in material performance. Kraig Labs continues to pursue a dual strategy of commercializing existing spider silk technology while investing in future innovations.
Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk manufacturing, has established production operations in Lam Dong Province, Vietnam's premier silk-producing region. This achievement follows the January 2025 issuance of a new Investment Registration Certificate (IRC), which was important for the company's expansion plans.
The establishment in Lam Dong Province represents the fulfillment of a decade-long strategic goal and positions the company to accelerate its production growth. The Department of Finance in Lam Dong has officially confirmed Kraig Labs' presence in the region, enabling the company to strengthen its supply chain and scale up its proprietary spider silk production.
CEO Kim Thompson described this development as a 'transformative moment' for the company, emphasizing their commitment to making significant investments to drive production to unprecedented levels while contributing to Vietnam's silk sector development.
Kraig Biocraft Laboratories (OTCQB: KBLB) has achieved a significant production milestone in spider silk manufacturing. The company has completed its largest single batch of BAM-1 recombinant spider silk, surpassing its entire 2024 production output in just one production run in early 2025.
The achievement follows a record-breaking 2024, where the company produced more spider silk than all previous years combined. This expansion demonstrates Kraig Labs' ability to scale up commercial production of its revolutionary spider silk technology for applications in technical textiles, defense, and performance apparel industries.
According to COO Jon Rice, this milestone validates the company's robust spider silk production platform and its capability to deliver industrial-scale quantities of this advanced biomaterial. The company aims to meet what it perceives as substantial global demand for high-performance spider silk.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced a significant breakthrough in its genetic research program, successfully doubling the complexity and size of its spider silk gene insert package. This advancement aims to enhance the performance characteristics of their spider silk fibers, including strength, elasticity, and durability.
The company is pursuing a dual strategy: advancing research while maintaining focus on commercial production. CEO Kim Thompson emphasizes the potential of larger gene insert packages to unlock superior material characteristics, while COO Jon Rice confirms they remain on track for commercial-scale manufacturing and material sales this year.
The breakthrough is expected to impact applications across technical textiles, defense, and medical industries. Kraig Labs continues to position itself as a global leader in spider silk technology, balancing innovation with production to meet market demand for these bioengineered materials.